phrykt

Amylyx Pharmaceuticals, Inc. (AMLX): who owns it and who trades it

As of Nov 16, 2026, AMLX insiders reported 38 open-market sales worth $17.2M and 2 purchases worth $152K in the last 12 months, with 46% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joshua B Cohen (CEO), with $6.6M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Amylyx Pharmaceuticals

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AMLX

207 funds and institutions reported AMLX shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.0%
BlackRock, Inc.7.9%
Perceptive Advisors LLC7.5%
TCG Crossover Management, LLC5.6%
Commodore Capital LP5.1%
Jupiter Topco LLC4.7%
Saturn V Capital Management LP4.2%
Vanguard Capital Management LLC3.8%
Morgan Stanley2.8%
Driehaus Capital Management LLC2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)16.73M15.04%$300M+1%
BlackRock, Inc.8.83M7.94%$159MNo change
Perceptive Advisors LLC8.33M7.50%$150M+1%
TCG Crossover Management, LLC6.24M5.62%$112MNo change
Commodore Capital LP5.65M5.08%$101MNo change
Jupiter Topco LLC5.24M4.71%$94M–
Saturn V Capital Management LP4.62M4.16%$83M+6%
Vanguard Capital Management LLC4.22M3.80%$75.9M+2%
Morgan Stanley3.13M2.82%$56.2M+44%
Driehaus Capital Management LLC3.04M2.73%$54.5M+2%
First Light Asset Management, LLC3.02M2.72%$54.3M-5%
Franklin Resources Inc2.95M2.65%$53M+30%
Goldman Sachs Group Inc2.86M2.57%$51.3M+9%
State Street Corp2.60M2.34%$46.8M+10%
Geode Capital Management, LLC2.34M2.10%$41.9M+6%
Adage Capital Partners Gp, L.l.c.1.90M1.71%$34.1M-47%
JPMorgan Chase & Co1.86M1.68%$34.9M–
Siren, L.L.C.1.48M1.33%$26.6M+20%
Eventide Asset Management, LLC1.33M1.19%$23.8M-12%
683 Capital Management, LLC1.28M1.15%$23M-16%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AMLX insiders reported $152K of open-market purchases and $17.2M of sales. 46% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$152K
2 trades, 1 people
Sales, 12 months
$17.2M
38 trades, 6 people
Sales under a 10b5-1 plan
46%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$7.2M$7.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026James M FratesCFOSale plan12,800$30.32$388KForm 4
Nov 10, 2026James M FratesCFOSale plan7,200$30.97$223KForm 4
Nov 9, 2026Joshua B CohenCEOSale plan38,105$29.39$1.1MForm 4
Nov 9, 2026Joshua B CohenCEOSale plan61,895$30.11$1.9MForm 4
Nov 9, 2026Justin B. KleeCEOSale plan37,483$29.39$1.1MForm 4
Nov 9, 2026Justin B. KleeCEOSale plan62,517$30.11$1.9MForm 4
Nov 9, 2026James M FratesCFOSale plan7,700$29.39$226KForm 4
Nov 9, 2026James M FratesCFOSale plan12,300$30.11$370KForm 4
Oct 5, 2026George M Milne JrDirectorSale plan30,000$27.70$831KForm 4
Sep 10, 2026Camille L BedrosianChief Medical OfficerSale7,947$32.21$256KForm 4
Sep 10, 2026Camille L BedrosianChief Medical OfficerSale2,081$33.09$68.9KForm 4
Sep 10, 2026James M FratesCFOSale9,768$32.27$315KForm 4
Sep 10, 2026James M FratesCFOSale1,042$33.23$34.6KForm 4
Sep 10, 2026Gina MazzarielloChief Legal OfficerSale9,525$32.46$309KForm 4
Sep 10, 2026Gina MazzarielloChief Legal OfficerSale11$33.34$367Form 4
Sep 10, 2026Joshua B CohenCEOSale919$33.15$30.5KForm 4
Sep 10, 2026Joshua B CohenCEOSale29,545$32.16$950KForm 4
Sep 10, 2026Justin B. KleeCEOSale1,439$33.16$47.7KForm 4
Sep 10, 2026Justin B. KleeCEOSale29,025$32.13$933KForm 4
Jul 10, 2026Gina MazzarielloChief Legal OfficerSale15,000$17.61$264KForm 4
Jul 9, 2026Gina MazzarielloChief Legal OfficerSale15,000$18.32$275KForm 4
May 21, 2026Karen FirestoneDirectorPurchase3,800$13.51$51.3KForm 4
Mar 2, 2026Justin B. KleeCEOSale29,282$14.47$424KForm 4
Mar 2, 2026Joshua B CohenCEOSale29,282$14.48$424KForm 4
Mar 2, 2026Camille L BedrosianChief Medical OfficerSale6,461$14.58$94.2KForm 4
Mar 2, 2026James M FratesCFOSale7,909$14.52$115KForm 4
Mar 2, 2026Gina MazzarielloChief Legal OfficerSale6,844$14.52$99.4KForm 4
Feb 23, 2026Gina MazzarielloChief Legal OfficerSale3,419$14.14$48.3KForm 4
Feb 2, 2026James M FratesCFOSale3,557$14.65$52.1KForm 4
Feb 2, 2026Joshua B CohenCEOSale15,500$14.68$228KForm 4
Feb 2, 2026Gina MazzarielloChief Legal OfficerSale3,448$14.65$50.5KForm 4
Feb 2, 2026Justin B. KleeCEOSale15,500$14.69$228KForm 4
Jan 16, 2026Joshua B CohenCEOSale1,974$13.83$27.3KForm 4
Jan 16, 2026Justin B. KleeCEOSale1,995$13.89$27.7KForm 4
Jan 15, 2026Joshua B CohenCEOSale136,193$13.59$1.9MForm 4
Jan 15, 2026Justin B. KleeCEOSale136,193$13.58$1.8MForm 4
Jan 6, 2026James M FratesCFOSale3,326$11.11$37KForm 4
Jan 6, 2026Joshua B CohenCEOSale7,715$11.09$85.6KForm 4
Dec 23, 2025Karen FirestoneDirectorPurchase8,100$12.45$101KForm 4
Dec 1, 2025Camille L BedrosianChief Medical OfficerSale6,580$14.35$94.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joshua B CohenCo-Chief Executive Officer, Director–$6.6MNov 9, 2026
Justin B. KleeCo-Chief Executive Officer, Director–$6.5MNov 9, 2026
James M FratesChief Financial Officer–$1.8MNov 10, 2026
Gina MazzarielloChief Legal Officer–$1MSep 10, 2026
George M Milne JrDirector–$831KOct 5, 2026
Camille L BedrosianChief Medical Officer–$513KSep 10, 2026
Karen FirestoneDirector$152K–May 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AMLX short interest

Moderate short interest. 10.0% of AMLX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 12%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.82M AMLX shares were sold short, 10.0% of the shares outstanding, down 3.2% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 10.5 trading days (days to cover).

Shares short, % of all shares

9.97%May 15Oct 3014.0%

Days to cover

10.5May 15Oct 3018.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.82M9.97%-3%1.22M10.5
Oct 15, 202613.25M11.89%+5%1.33M9.9
Sep 30, 202612.67M11.37%-6%1.38M9.2
Sep 15, 202613.51M12.13%+6%1.56M8.6
Aug 31, 202612.74M11.43%-5%5.38M2.4
Aug 14, 202613.43M12.05%+0%1.88M7.1
Jul 31, 202613.40M12.03%+9%1.96M6.8
Jul 15, 202612.27M11.03%-15%1.33M9.2
Jun 30, 202614.39M12.94%+10%2.04M7.1
Jun 15, 202613.12M11.80%-12%1.62M8.1
May 29, 202614.96M13.45%+3%916,13916.3
May 15, 202614.51M13.05%-2%1.19M12.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Amylyx Pharmaceuticals company events

Amylyx Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 8, 2026AgreementAmylyx Pharmaceuticals, Inc. entered into a Manufacturing and Supply Agreement with Bachem Americas, Inc. and on September 1, 2026, the Company entered into a term sheet with Polypeptide Group AG, pursuant to which Bachem and Polypeptide, respectively, will manufacture and supply the Company’s… Filing
  3. Aug 20, 2026AgreementAmylyx Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Morgan Stanley & Co. LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC, as representatives of the several underwriters named therein, relating to the issuance and sale of an aggregate of 14,090,000… Filing
  4. Aug 18, 2026AnnouncementAmylyx Pharmaceuticals, Inc. hosted a conference call with investors and analysts to discuss positive topline results from the LUCIDITY Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. Filing
  5. Aug 18, 2026AnnouncementThe Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 receptor antagonist, in… Filing
  6. Aug 6, 2026ResultsReleased financial results. Filing
  7. Jun 4, 2026VoteReported shareholder vote results. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Mar 24, 2026AnnouncementShared information with investors. Filing
  10. Mar 3, 2026ResultsReleased financial results. Filing
  11. Jan 8, 2026AnnouncementAmylyx Pharmaceuticals, Inc. announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Amylyx Pharmaceuticals financials

Famous investors that hold AMLX

4 of the 50 well-known investors we track reported holding AMLX in their latest 13F filing. The largest position is Ken Griffin's, worth $14.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026488,571$14.2M0.0%+173%
Steve Cohen · Point72 Asset ManagementQ3 2026388,699$11.3M0.0%New
Israel Englander · Millennium ManagementQ3 2026191,689$5.6M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202672,935$2.1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AMLX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Perceptive Advisors LLC13G/A8.2%
Nov 16, 2026Commodore Capital LP13G/A1.6%
Nov 16, 2026Commodore Capital LP13G/A1.6%
Nov 16, 2026Perceptive Advisors LLC13G/A8.2%

Questions about Amylyx Pharmaceuticals, Inc. (AMLX) stock

Who owns the most AMLX stock?

The largest reported owner of Amylyx Pharmaceuticals, Inc. (AMLX) is FMR LLC (Fidelity), with 15.0% of the company. In total, 207 funds and institutions reported holding AMLX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are AMLX insiders buying or selling?

In the last 12 months, AMLX insiders reported 2 open-market purchases worth $152K and 38 sales worth $17.2M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in AMLX?

As of Oct 30, 2026, 12.82M AMLX shares were sold short, 10.0% of the shares outstanding, down 3.2% from the report before. At the average daily volume of 1.22M shares, buying them all back would take about 10.5 trading days (days to cover). See the history.

Which famous investors hold AMLX?

4 of the 50 well-known investors we track reported AMLX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $14.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.